[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186. [2] El-Kassas M, Cabezas J, Coz P I, et al. Nonalcoholic fatty liver disease: current global burden. Semin Liver Dis, 2022,42(3):401-412. [3] Tomic D, Kemp W W, Roberts S K. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol, 2018,30(10):1103-1115. [4] Le MH, Yeo Y H, Li X, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2022,20(12):2809-2817. [5] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology, 2019,70(4):1119-1133. [6] Tao Z, Li Y, Cheng B, et al. Influence of nonalcoholic fatty liver disease on the occurrence and severity of chronic kidney disease. J Clin Transl Hepatol, 2022,10(1):164-173. [7] Venniyoor A, Al F A, Al B B. The troubling link between non-alcoholic fatty liver disease (NAFLD) and extrahepatic cancers (EHC). Cureus, 2021,13(8):e17320. [8] 崔姗姗, 刘英, 江霞. 非酒精性脂肪性肝病与IR的研究进展. 医学信息, 2022,35(10):66-69. [9] Li Y, Zheng R, Li J, et al. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study. Lipids Health Dis, 2020,19(1):229. [10] Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol, 2012,56(5):1145-1151. [11] Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int, 2006,26(7):856-863. [12] 杨燕, 姚艺璇, 洪秀韬, 等. 应用IR替代指标评估2型糖尿病患者非酒精性脂肪肝及进展性肝纤维化的价值. 中华内分泌代谢杂志, 2021,37(4):281-287. [13] 骆星谕, 范芳芳, 贾佳, 等. 北京社区居民甘油三酯葡萄糖乘积指数与新发颈动脉斑块风险的研究. 中国心血管病研究, 2023,21(1):18-24. [14] Guerrero-Romero F, Simental-Mendia L E, Gonzalez-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab, 2010,95(7):3347-3351. [15] Miyake T, Kumagi T, Hirooka M, et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J Gastroenterol, 2013,48(3):413-422. [16] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 2015,149(2):367-378, e14-e15. [17] Younossi Z M, Corey K E, Lim J K. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology, 2021,160(3):912-918. [18] Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia, 2004,47(8):1360-1369. [19] Zhang S, Du T, Zhang J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis, 2017,16(1):15. [20] Zhu J Z, Zhou Q Y, Wang Y M, et al. Prevalence of fatty liver disease and the economy in China: a systematic review. World J Gastroenterol, 2015,21(18):5695-5706. [21] Ekstedt M, Franzen L E, Mathiesen U L, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006,44(4):865-873. [22] 梁烨倍, 杨春光, 王昆凤, 等. 云南省布朗族成人非酒精性脂肪性肝病流行特点研究. 实用肝脏病杂志, 2022,25(2):223-226. |